DePuy Synthes acquires bone defect-treating 3D printing technology

111

DePuy Synthes has acquired 3D printing technology from Tissue Regeneration Systems (TRD). The 3D printing methods developed by TRS are designed to create patient-specific, bioresorbable implants with a unique mineral coating intended to support bone healing in patients with orthopaedic and craniomaxillofacial deformities and injuries.

Financial terms of the transaction have not been disclosed.

“We are systematically investing in building a pipeline of 3D-printed products,” says Ciro Römer, Company Group Chairman, DePuy Synthes. “The TRS technology…will be added to the DePuy Synthes Trauma Platform.”

DePuy Synthes began collaborating with TRS in 2014 through Johnson & Johnson Innovation. Founded in 2008, TRS is an early-stage medical device company headquartered in Plymouth, USA, commercialising skeletal reconstruction and bone regeneration technology based on research performed at the University of Michigan, Ann Arbor, USA, and the University of Wisconsin, Madison, USA.

LEAVE A REPLY